Could poison gas heal lungs? small trial tests carbon monoxide for ARDS
NCT ID NCT03799874
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested whether inhaling low doses of carbon monoxide (200 ppm for 90 minutes daily for 3 days) is safe and helpful for people with acute respiratory distress syndrome (ARDS), a severe lung condition. Only 4 intubated adults participated, making this a very small study. The main goal was to check for side effects and measure changes in a blood marker of cell damage.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- inhaled carbon monoxide
- What this could lead to
- If it works, this could point toward a new treatment for ARDS, a severe lung condition with few options.
- What could go wrong
- This is a very small, early-phase trial with only 4 participants, so results are not reliable. Carbon monoxide is toxic at high levels, and safety is a major concern.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
4 people
The number who actually took part.
- Started
-
Sep 2019
- Finished
-
Apr 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: All intubated patients ≥ 18 years old with ARDS 1. ARDS is defined when all four of the following criteria are met: 1. A PaO2/FiO2 ratio ≤ 300 with at least 5 cm H2O positive end-expiratory airway pressure (PEEP) 2. Bilateral opacities on frontal chest radiograph (not fully explained by effusions, lobar/lung collapse, or nodules) within 1 week of a known clinical insult or new or worsening respiratory symptoms 3. A need for positive pressure ventilation by an endotracheal or tracheal tube 4. Respiratory failure not fully explained by cardiac failure or fluid overload; need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor present. 2. ARDS onset is defined as the time the last of criteria 1-4 are met. ARDS must persist through the enrollment time window of 168 hours. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Age less than 18 years 2. Greater than 168 hours since ARDS onset 3. Pregnant or breastfeeding 4. Prisoner 5. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest) 6. No consent/inability to obtain consent or appropriate legal representative not available 7. Physician refusal to allow enrollment in the trial 8. Moribund patient not expected to survive 24 hours 9. No arterial or central line/no intent to place an arterial or central line 10. No intent/unwillingness to follow lung protective ventilation strategy 11. Severe hypoxemia defined as SpO2 \< 95 or PaO2 \< 90 on FiO2 ≥ 0.9 12. Hemoglobin \< 7.0 g/dL 13. Subjects who are Jehovah's Witnesses or are otherwise unable or unwilling to receive blood transfusions during hospitalization 14. Acute myocardial infarction (MI) or acute coronary syndrome (ACS) within the last 90 days 15. Coronary artery bypass graft (CABG) surgery within 30 days 16. Angina pectoris or use of nitrates with activities of daily living 17. Cardiopulmonary disease classified as NYHA class IV 18. Stroke (ischemic or hemorrhagic) within the prior 1 month, cardiac arrest requiring CPR within the prior 72 hours, or inability to assess mental status following cardiac arrest 19. Burns \> 40% total body surface area (TBSA) 20. Severe airway inhalational injury 21. Use of high frequency oscillatory ventilation 22. Use of extracorporeal membrane oxygenation (ECMO) 23. Concomitant use of inhaled pulmonary vasodilator therapy (eg. nitric oxide \[NO\] or prostaglandins) 24. Diffuse alveolar hemorrhage from vasculitis 25. Concurrent participation in other investigational drug study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Duke Regional Hospital
Durham, North Carolina, 27704, United States
-
Duke University Hospital
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
New York-Presbyterian Brooklyn Methodist Hospital
Brooklyn, New York, 11215, United States
-
Washington University
St Louis, Missouri, 63130, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donated immune cells calm the cytokine storm?
- Steroid dose showdown: can more dexamethasone save lives in respiratory failure?
- Breathing machine settings put to the test in severe lung injury
- The hidden breath: how a mismatch between patient and machine may shape ARDS recovery
- Scientists hunt for hidden subgroups in sudden respiratory failure
- AI plus ultrasound could catch heart and lung decline before it turns critical